Clinical consequences of polymorphic acetylation of basic drugs.
Drayer, D E
Clinical consequences of polymorphic acetylation of basic drugs. [electronic resource] - Clinical pharmacology and therapeutics Sep 1977 - 251-8 p. digital
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
0009-9236
10.1002/cpt1977223251 doi
Acetylation
Antibodies, Antinuclear
Biotransformation
Chemical and Drug Induced Liver Injury--etiology
Humans
Hydralazine--adverse effects
Isoniazid--adverse effects
Lupus Erythematosus, Systemic--chemically induced
Pharmaceutical Preparations--metabolism
Phenelzine--adverse effects
Phenotype
Polymorphism, Genetic
Procainamide--adverse effects
Sulfasalazine--adverse effects
Clinical consequences of polymorphic acetylation of basic drugs. [electronic resource] - Clinical pharmacology and therapeutics Sep 1977 - 251-8 p. digital
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
0009-9236
10.1002/cpt1977223251 doi
Acetylation
Antibodies, Antinuclear
Biotransformation
Chemical and Drug Induced Liver Injury--etiology
Humans
Hydralazine--adverse effects
Isoniazid--adverse effects
Lupus Erythematosus, Systemic--chemically induced
Pharmaceutical Preparations--metabolism
Phenelzine--adverse effects
Phenotype
Polymorphism, Genetic
Procainamide--adverse effects
Sulfasalazine--adverse effects